亚胺培南与莫西沙星治疗重症肺炎的临床疗效对比  

Comparison of Imipenem and Moxifloxacin in the Treatment of Severe Pneumonia

作　　者：苏行[1] 陈宏碧[1] 王行表 SU Hang;CHEN Hongbi;WANG Xingbiao(Mianyang Central Hospital,Mianyang,Sichuan 621000,China)

机构地区：[1]绵阳市中心医院,四川绵阳621000

出　　处：《大医生》2020年第5期112-114,共3页Doctor

摘　　要：目的对比分析重症肺炎患者应用亚胺培南与莫西沙星治疗的临床效果。方法选取2019年1月至10月绵阳市中心医院治疗的82例重症肺炎患者为研究对象,采用抽签分组法分成对照组与试验组,每组41例。对照组患者予以莫西沙星治疗,试验组患者予以亚胺培南治疗,对比两组患者临床疗效、治疗前后炎性介质水平、不良反应发生率。结果试验组患者临床治疗总有效率为97.56%,高于对照组的82.93%,差异有统计学意义(P<0.05)。治疗后试验组患者C反应蛋白(CRP)、降钙素原(PCT)、白介素-6(IL-6)水平分别为(10.45±3.10)ng/L、(4.23±0.88)μg/L、(10.25±2.67)ng/L,对照组分别为(16.24±3.24)ng/L、(6.65±0.97)μg/L、(18.17±3.59)ng/L,治疗后两组患者CRP、PCT、IL-6水平均低于治疗前,且治疗后试验组患者均低于对照组,差异有统计学意义(P<0.05)。试验组患者不良反应发生率为9.76%,对照组为12.20%,组间差异无统计学意义(P>0.05)。结论与莫西沙星相比,亚胺培南治疗重症肺炎的效果更加理想,能够进一步减轻患者炎性反应,且不会增加不良发应。Objective To compare and analyze the clinical effect of imipenem and moxifloxacin in the treatment of severe pneumonia.Methods A total of 82 patients with severe pneumonia treated in mianyang central hospital from January to October 2019,were selected as the study subjects,and divided into the control group and the experimental group by random lottery,with 41 patients in each group.Moxifloxacin was given to patients in the control group and imipenem was given to patients in the experimental group.Clinical efficacy,levels of inflammatory mediators before and after treatment,and incidence of adverse reactions were compared between the two groups.Results The total clinical effective rate of the experimental group was 97.56%,higher than that of the control group(82.93%),the difference was statistically significant(P<0.05).After treatment,the levels of C-reactive protein(CRP),procalcitonin(PCT)and interleukin-6(IL-6)in the experimental group were(10.45±3.10)ng/L,(4.23±0.88)u g/L and(10.25±2.67)ng/L,respectively,while those in the control group were(16.24±3.24)ng/L,(6.65±0.97)g/L and(18.17±3.59)ng/L,after treatment,CRP,PCT,IL-6 level in the experimental group was significantly lower than that in the control group,and CRP,PCT,IL-6 level in the control group was significantly lower than that in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions was 9.76%in the experimental group and 12.20%in the control group,with no statistically significant difference between the groups(P>0.05).Conclusion Compared with moxixacin,imipenem is more effective in the treatment of severe pneumonia,which can further reduce the inflammatory response of patients without significantly increasing the adverse reactions.Therefore.

关 键 词：重症肺炎 亚胺培南 莫西沙星 炎性介质 

分 类 号：R47[医药卫生—护理学]